NICE recommends GLP-1 receptor agonists for type 2 diabetes when metformin and other oral medications fail to achieve adequate glycaemic control, particularly with BMI 35 kg/m or weight-related comorbidities
This is not a replacement for trials, but it can move much faster, and that speed matters when a drug goes from niche to mainstream almost overnight, said senior author of the study, Sharath Chandra Guntuku, Research Associate Professor in Computer and Information Science at the University of Pennsylvania, in a press release
Skin & Antioxidant Outcome Oral Glutathione vs
Cardiovascular comorbidity in rheumatic diseases
Yu, Y., Liu, L., Wang, X., Liu, X., Liu, X., Xie, L., & Wang, G
What happened to Doves gradual tan